Beijing Balance Medical Technology Co

Beijing Balance Medical Technology Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Beijing Balance Medical Technology Co (688198.SS) as of Nov 20, 2026 is 205.80 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 161.00 M CNY — a change of 27.83% (higher).

EBITDA

205.80 MCNY

YoY

27.83%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Beijing Balance Medical Technology Co is 2025 205.80 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Beijing Balance Medical Technology Co was 2024 161.00 M CNY. It decreases by 27.83% higher compared to the previous year.

The Beijing Balance Medical Technology Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
44.06 M CNY
Jan 1, 2019
72.65 M CNY
Jan 1, 2020
52.90 M CNY
Jan 1, 2021
41.13 M CNY
Jan 1, 2022
91.03 M CNY
Jan 1, 2023
117.40 M CNY
Jan 1, 2024
161.00 M CNY
Jan 1, 2025
205.80 M CNY
The Beijing Balance Medical Technology Co EBITDA history
YEAREBITDAYoY
205.80 MCNY+27.83%
161.00 MCNY+37.13%
117.40 MCNY+28.97%
91.03 MCNY+121.35%
41.13 MCNY-22.26%
52.90 MCNY-27.18%
72.65 MCNY+64.91%
44.06 MCNY-7.69%
47.73 MCNY+18.71%
40.20 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beijing Balance Medical Technology Co Stock analysis

What does Beijing Balance Medical Technology Co do? Beijing Balance Medical Technology Co., Ltd. generates revenue through the manufacture and sale of biotechnology products across three key therapeutic areas. The company's heart valve replacement and repair segment offers artificial biological heart valves and valve forming rings, while its congenital heart disease interventional therapy line includes cardiothoracic surgical biological patches, outflow tract single valve patches, and atrial defect occluders. The surgical soft tissue repair division provides neurosurgical biological patches and biological hernia patches. All products are sold primarily within China's domestic market to hospitals and medical institutions seeking advanced cardiovascular and surgical solutions. The firm's product portfolio targets medical professionals specializing in cardiac surgery, congenital heart defect correction, and soft tissue repair procedures. Hospitals and healthcare providers in China purchase these biotechnology solutions for patient treatments, with the domestic market serving as the primary sales channel. The company's focus on specialized medical devices for heart valve procedures, congenital heart conditions, and surgical repair applications drives its revenue streams. Beijing Balance Medical Technology's business model centers on developing and distributing high-precision medical devices tailored to specific surgical needs. The domestic Chinese healthcare system represents the main customer segment, with hospitals and clinics purchasing the company's products for use in cardiac surgeries, congenital heart defect corrections, and soft tissue repair operations. The company's product range directly supports medical procedures requiring biological heart valves, congenital heart disease interventions, and surgical tissue repair solutions. Beijing Balance Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Beijing Balance Medical Technology Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Beijing Balance Medical Technology Co is 205.80 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Beijing Balance Medical Technology Co changed from 161.00 M CNY to 205.80 M CNY, representing a 27.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Beijing Balance Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Beijing Balance Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Beijing Balance Medical Technology Co

All Key Metrics — Beijing Balance Medical Technology Co